目的 分析2011—2013年貴港市人民醫(yī)院抗腫瘤藥物的使用情況和用藥趨勢(shì)。方法 通過(guò)回顧性檢索貴港市人民醫(yī)院HIS系統(tǒng)2011—2013年的數(shù)據(jù)，并對(duì)各類抗腫瘤藥物的銷售金額、銷售量及構(gòu)成比等進(jìn)行統(tǒng)計(jì)。結(jié)果 2011—2013年抗腫瘤藥物的銷售金額逐年增大，尤其抗代謝藥和植物來(lái)源抗腫瘤藥及其衍生物的增長(zhǎng)幅度較大，烷化劑類藥物的銷售金額卻呈下降趨勢(shì)。銷售金額前3位的抗腫瘤藥分別是吉西他濱、多西他賽、培美曲塞。銷量最大的抗腫瘤藥是氟尿嘧啶，其次是吉西他濱。結(jié)論 貴港市人民醫(yī)院抗腫瘤藥物的銷售金額增長(zhǎng)率接近全國(guó)水平，抗代謝藥和植物來(lái)源抗腫瘤藥及其衍生物的市場(chǎng)需求大，應(yīng)加大對(duì)其品種的生產(chǎn)和優(yōu)化力度。

Objective To analyze the usage of anticancer drugs in Guigang City People's Hospital from 2011 to 2013. Methods The data were drawn from the HIS system in the hospital retrospectively, and the consumption sum, sales volume, and component ratio of anticancer drugs were analyzed. Results Consumption sum of anticancer drugs increased year by year substantially during 2011－2013, especially antimetabolite and anticancer drugs from plants and their derivatives, but alkylating drugs showed a downward trend in demand. Consumption sum of top three drugs in anticancer drugs were gemcitabine, docetaxel, and pemetrexed. The largest sale of the anticancer drugs was fluorouracil, then was gemcitabine. Conclusion The growth rate of sales of anticancer drugs in Guigang City People's Hospital closes to the national level. The antimetabolite and anticancer drugs from plants and their derivatives have a big demand in the market, therefore the varieties of production and optimization should be intensified.